MiNK Therapeutics Q1 net loss $5.7M; agenT-797 shows durable responses in solid tumors

MiNK Therapeutics, Inc.

2023-Q1 EPS reported -$0.17

Net loss $5.7M ($0.17/share) vs $7.8M ($0.23) in Q1 2022; cash $14.9M at March 31, 2023.
agenT-797 + anti-PD-1 achieved 42% tumor reduction in metastatic gastric cancer lasting >9 months; durable disease stabilization in anti-PD-1 refractory NSCLC.
Initiating phase 1/2 expansion studies in NSCLC and gastric cancer; majority costs planned for external non-dilutive grant funding.
Upcoming presentations: FAP-CAR-iNKT at ASGCT May 19; agenT-797 in viral ARDS at ATS May 21.
Manufacturing capacity 5,000 doses/year, rapidly expanding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $5.7 million or $0.17 per share, EPS $0.17 per share.

Period: the quarter ended March 31, 2023
Net income: $5.7 million or $0.17 per share
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023, was $5.7 million or $0.17 per share

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-003188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.